Eli Lilly reported tirzepatide sales of $10.1 billion in Q3—surpassing prior drug sales leaders and making tirzepatide the world’s top‑selling medicine—then disclosed a $1.2 billion investment to build a Puerto Rico facility dedicated to its oral GLP‑1 candidate orforglipron. The company’s revenue guidance rose as tirzepatide demand broadens across diabetes and obesity indications. Lilly’s industrial expansion aims to secure supply for growing global demand for GLP‑1 therapies and to support lower‑frequency oral formulations in development.